Company intelligence / Profile preview

AOI Pharma

Fort Lee, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

AOI Pharma is a clinical-stage biotechnology company focused on developing innovative topical treatments for dermatological and immunological conditions. The company's lead candidate, AOI-101, is a proprietary topical formulation of tofacitinib, a Janus kinase (JAK) inhibitor. AOI Pharma aims to address the unmet needs of patients with atopic dermatitis, alopecia areata, and vitiligo by providing localized therapy that minimizes systemic exposure and associated side effects. Headquartered in New Jersey, the company operates as a subsidiary of the Japanese firm Aoi Pharmaceutical, leveraging its parent's manufacturing expertise to advance its clinical pipeline.

Therapeutic areas: Dermatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on AOI Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AOI Pharma.

Explore the full profile